Small sample.

An unplanned secondary analysis of OpACIN-neo indicates that, following neoadjuvant immune checkpoint inhibition for stage III melanoma, path response in the largest lymph node with viable or treated tumor present was concordant with response in the entire dissection bed in 81 of 82 cases (99%), meaning initial clinical nodal involvement may not always necessitate full dissection. | Reijers, JAMA Surg 2022